CoChat

Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies

Harbi, Emirhan, Aschner, Michael · 2025 · Molecular Biology Reports
Cited by 18

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11033-025-10403-8

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 61

  1. Chittiboina P, Lonser RR (2015) Von Hippel-Lindau disease. Handbook of clinical neurology. pp. 139–156 · DOI · Paper page
  2. Leeuwaarde AS, van Nesselrooij B (2024) Von Hippel-Lindau syndrome. GeneReviews, s.l.
  3. Devarajan P, De Leon M, Talasazan F, Schoenfeld AR, Davidowitz EJ, Burk RD (2001) The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways. J Biol Chem pp. 40599–40605 · DOI
  4. Ohh M, Taber CC, Ferens FG, Tarade D (2022) Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata. eLife p. e80774 · DOI
  5. Choueiri. TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S (2013) The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin cancer Research: Official J Am Association Cancer Res pp. 5218–5226 · DOI
  6. Peng S, Zhang J, Tan X, Huang Y, Xu J, Silk N, Zhang D, Liu Q, Jiang J (2020) The VHL/HIF Axis in the development and treatment of pheochromocytoma/paraganglioma. Front Endocrinol · DOI
  7. Schmid S, Gillessen S, Binet I, Brändle M, Engeler D, Greiner J, Hader C, Heinimann K, Kloos P, Krek W, Krull I, Stoeckli SJ, Sulz MC, van Leyen K, Weber J, Rothermundt C, Hundsberger T (2014) Management of von hippel-lindau disease: an interdisciplinary review. Oncol Res Treat pp. 761–771 · DOI
  8. Kim (2018) Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies. Frontiers in pediatrics. · DOI
  9. van Leeuwaarde, Ahmad S, van Nesselrooij B et al (2000) Von Hippel-Lindau syndrome. GeneReviews® [Internet], s.l.
  10. del Peso L, Castellanos MC, Temes E, Martin-Puig S, Cuevas Y, Olmos G, Landazuri MO (2003) The von Hippel Lindau/hypoxia-inducible factor (HIF) pathway regulates the transcription of the HIF-proline hydroxylase genes in response to low oxygen. J Biol Chem pp. 48690–48695 · DOI · Paper page
  11. Zhang J, Zhang Q (2018) VHL and hypoxia signaling: beyond HIF in Cancer. Biomedicines · DOI
  12. Ohh. M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr, Iliopoulos O (1998) The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell pp. 959–968 · DOI · Paper page
  13. Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG Jr, Ohh M (2004) pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol pp. 3251–3261 · DOI · Paper page
  14. Roe JS, Youn HD The positive regulation of p53 by the tumor suppressor VHL. Cell cycle (Georgetown, Tex.). 2006, pp. 2054–2056 · DOI
  15. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W (2003) Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol pp. 64–70 · DOI · Paper page
  16. Klingler JH, Gläsker S, Bausch B, Urbach H, Krauss T, Jilg CA, Steiert C, Puzik A, Neumann-Haefelin E, Kotsis F, Agostini H, Neumann HPH, Beck J (2020) Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Child’s Nerv Syst pp. 2537–2552 · doi:10.1007/s00381-020-04712-5
  17. Dollfus H, Massin P, Taupin P, Nemeth C, Amara S, Giraud S, Béroud C, Dureau P, Gaudric A, Landais P, Richard S (2002) Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Investig Ophthalmol Vis Sci pp. 3067–3074
  18. Wiley HE, Krivosic V, Gaudric A, Gorin MB, Shields C, Shields J, Aronow ME, Chew E (2019) Y. MANAGEMENT OF RETINAL HEMANGIOBLASTOMA IN VON HIPPEL-LINDAU DISEASE. Retina (Philadelphia, Pa.). pp. 2254–2263 · DOI
  19. Castro-Teles J, Sousa-Pinto B, Rebelo S, Pignatelli D (2021) Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: not a needle in a haystack. Endocr Connections pp. R293–R304 · DOI
  20. Frederik JWM, Höppener, Cornelis JM (2003) Lips. Pheochromocytoma in von Hippel-Lindau disease. J Clin Endocrinol Metabolism pp. 969–974 · DOI
  21. Kantorovich V, Pacak K (2010) Pheochromocytoma and paraganglioma. Prog Brain Res pp. 343–373 · DOI
  22. Akirov A, Larouche V, Alshehri S, Asa SL, Ezzat S (2019) Treatment options for pancreatic neuroendocrine tumors. Cancers · DOI
  23. Hackert T, Büchler MW, Werner J (2011) Current state of surgical management of pancreatic cancer. Cancers pp. 1253–1273 · DOI
  24. Kim (2005) Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg pp. 503–512 · doi:10.3171/jns.2005.102.3.0503
  25. Choyke PL, Glenn GM, Wagner JP, Lubensky IA, Thakore K, Zbar B, Linehan WM, Walther MM (1997) Epididymal cystadenomas in von Hippel-Lindau disease. Urology pp. 926–931 · DOI
  26. Haase (2006) The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int pp. 1302–1307 · DOI · Paper page
  27. Na X, Wu G, Ryan CK, Schoen SR, di’Santagnese PA, Messing EM (2003) Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol pp. 588–592 · DOI · Paper page
  28. Kim., Zschiedrich S (2018) Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies. Frontiers in pediatrics. · DOI
  29. Pastore AL, Palleschi G, Silvestri L, Moschese D, Ricci S, Petrozza V, Carbone A, Di Carlo A (2015) Serum and urine biomarkers for human renal cell carcinoma. Dis Markers · DOI
  30. Zhu W, Zheng G, Yan X, Liu M, Li X, Cheng Y, Bai C, Zhang Y, Huo L (2024) Diagnostic efficacy of [68Ga]Ga-NY104 PET/CT to identify clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging pp. 4127–4133 · doi:10.1007/s00259-024-06801-y
  31. Friedrich (1999) Von Hippel-Lindau syndrome. A pleomorphic condition. Cancer pp. 2478–2482 · DOI · Paper page
  32. Rednam SP, Erez A, Druker H, Janeway KA, Kamihara J, Kohlmann WK, Nathanson KL, States LJ, Tomlinson GE, Villani A, Voss SD, Schiffman JD, Wasserman JD (2017) Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood. Clin cancer Research: Official J Am Association Cancer Res pp. e68–e75 · DOI · Paper page
  33. Hudler P, Urbancic M (2022) The role of VHL in the development of von Hippel-Lindau disease and erythrocytosis. Genes · DOI
  34. Casey RT, Warren AY, Martin JE, Challis BG, Rattenberry E, Whitworth J, Andrews KA, Roberts T, Clark GR, West H, Smith PS, Docquier FM, Rodger F, Murray V, Simpson HL, Wallis Y, Giger O, Tran M (2017) Tomkin. Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. The Journal of clinical endocrinology and metabolism. pp. 4013–4022 · DOI
  35. Garg MK, Kharb S, Brar KS, Gundgurthi A, Mittal R (2011) Medical management of pheochromocytoma: role of the endocrinologist. Indian J Endocrinol Metabol pp. S329–S336 · DOI
  36. Václavík J, Stejskal D, Lacnák B, Lazárová M, Jedelský L, Kadalová L, Janosová M, Frysák Z, Vlcek P (2007) Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens pp. 1427–1431 · DOI · Paper page
  37. Bílek R, Vlček P, Šafařík L, Michalský D, Novák K, Dušková J, Václavíková E, Widimský J, Jr, Zelinka T (2019) Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. Cancers. · DOI
  38. Carrasquillo JA, Chen CC, Jha A, Ling A, Lin FI, Pryma DA, Pacak K (2021) Imaging of pheochromocytoma and paraganglioma. J Nuclear Medicine: Official Publication Soc Nuclear Med pp. 1033–1042 · DOI
  39. Timmers HJLM, Taïeb D, Pacak K, Lenders J (2024) W. M. Imaging of pheochromocytomas and paragangliomas. Endocr Rev pp. 414–434 · DOI
  40. Pacak K (2007) Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab pp. 4069–4079 · DOI · Paper page
  41. Ramachandran R, Rewari V (2017) Current perioperative management of pheochromocytomas. Indian J Urology: IJU: J Urol Soc India pp. 19–25 · DOI
  42. Öberg K (2018) Management of functional neuroendocrine tumors of the pancreas. Gland surgery. pp. 20–27 · DOI
  43. Tirosh A, Sadowski SM, Linehan WM, Libutti SK, Patel D, Nilubol N, Kebebew E (2018) Association of VHL genotype with pancreatic neuroendocrine tumor phenotype in patients with von Hippel-Lindau disease. JAMA Oncol. pp. 124–126 · DOI
  44. Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA (2020) & P. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. pp. 1–33 · DOI · Paper page
  45. Lee A, Chan DL, Wong MH, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N (2017) Systematic review of the role of targeted therapy in metastatic neuroendocrine tumors. Neuroendocrinology pp. 209–222 · doi:10.1159/000446115
  46. Hong B, Ma K, Zhou J, Zhang J, Wang J, Liu S, Zhang Z, Cai L, Zhang N, Gong K (2019) Frequent mutations of VHL gene and the clinical phenotypes in the largest Chinese cohort with von Hippel-Lindau disease. Front Genet · doi:10.3389/fgene.2019.00867
  47. Zanoletti E, Girasoli L, Borsetto D, Opocher G, Mazzoni A, Martini A (2017) Endolymphatic sac tumour in von Hippel-Lindau disease: management strategies. Acta otorhinolaryngologica Italica: organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale. pp. 423–429 · doi:10.14639/0392-100x-1402
  48. Offergeld C, Brase C, Yaremchuk S, Mader I, Rischke HC, Gläsker S, Schmid KW, Wiech T, Preuss SF, Suárez C, Kopeć T, Patocs A, Wohllk N, Malekpour M, Boedeker CC, Neumann HP (2012) Head and neck paragangliomas: clinical and molecular genetic classification. Clinics (Sao Paulo, Brazil). pp. 19–28 · DOI · Paper page
  49. Kaelin (2022) Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J Clin Investig p. e162480 · DOI · Paper page
  50. Else T, Wong KK, Frey KA, Brooks AF, Viglianti BL, Raffel DM (2024) 3-[18F]Fluoro-para-hydroxyphenethylguanidine (3-[18F]pHPG) PET-A novel imaging modality for paraganglioma. J Endocr Soc · DOI
  51. Fang F, Ding L, He Q, Liu M (2020) Preoperative Management of Pheochromocytoma and Paraganglioma. Frontiers in endocrinology. · DOI
  52. Mehta GU, Shively SB, Gläsker S, Bechert CJ, Zhuang Z, Raffeld M, Lonser RR, Oldfield EH, Vortmeyer AO (2007) Von Hippel-Lindau disease: epididymal cystadenoma targeted by metastatic events. Urology · doi:10.1016/j.urology.2007.03.047
  53. Odrzywolski KJ, Mukhopadhyay S (2010) Papillary cystadenoma of the epididymis. Arch Pathol Lab Med pp. 630–633 · DOI
  54. Papadakis GZ, Millo C, Sadowski SM, Bagci U, Patronas NJ (2016) Epididymal cystadenomas in von Hippel-Lindau disease showing increased activity on 68Ga DOTATATE PET/CT. Clin Nucl Med pp. 781–782 · DOI
  55. Lehmann H, Vicari D, Wild PJ, Frew IJ (2015) Combined deletion of Vhl and Kif3a accelerates renal cyst formation. J Am Soc Nephrology: JASN pp. 2778–2788 · DOI
  56. van Asselt SJ, de Vries EG, van Dullemen HM, Brouwers AH, Walenkamp AM, Giles RH, Links TP (2013) Pancreatic cyst development: insights from von Hippel-Lindau disease. Cilia · DOI
  57. Ayloo S, Molinari M (2016) Pancreatic manifestations in von Hippel-Lindau disease: A case report. Int J Surg Case Rep pp. 70–72 · doi:10.1016/j.ijscr.2016.02.031
  58. Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB, Tirosh A (2022) & Pancreatic manifestations recommendations development subcommittee of the VHL alliance. Management recommendations for pancreatic manifestations of von Hippel-Lindau disease. Cancer pp. 435–446 · DOI · Paper page
  59. Slater A, Moore NR, Huson SM (2003) The natural history of cerebellar hemangioblastomas in von Hippel-Lindau disease. AJNR Am J Neuroradiol pp. 1570–1574
  60. Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Höfler H, Latif F, Lerman MI, Zbar B, Neumann HP (1995) Von Hippel-Lindau (VHL) disease with pheochromocytoma in the black forest region of Germany: evidence for a founder effect. Hum Genet pp. 551–556 · DOI · Paper page
  61. Liu P, Zhu F, Li M, Dube DA, Liu Q, Wang C, Xiao Q, Zhang L, Gao S, Li Z, Zhang B, Liu J, Liu L, Chen X (2019) Von Hippel-Lindau black forest mutation inherited in a large Chinese family. Gland Surg pp. 343–353 · doi:10.21037/gs.2019.08.03

Metadata

Authors
Harbi, E., & Aschner, M.
Venue
Molecular Biology Reports
Published
2025-03-05
Volume
52
Issue
1
ISSN
  • 0301-4851
  • 1573-4978
Cited by
18
References
7
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies. https://app.cochat.ai/papers/10.1007/s11033-025-10403-8
The paper
Harbi, E., & Aschner, M. (2025). Von Hippel-Lindau syndrome: clinical features, genetic foundations, and management strategies. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-10403-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.